ArticleNature communications2022
SARS CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.1field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 32 citations in OpenAlex.
- COVID-19 mRNA Vaccines as Antigen-Agnostic Immunomodulators: A Repurposing Perspective.Medical sciences (Basel, Switzerland) · 2026Review
- HIV-1 viral load and reservoir size remain stable following SARS-CoV-2 mRNA vaccination in people with HIV.HIV medicine · 2026Article
- Review
- Potential Impact of SARS-CoV-2 Spike Protein on HIV-1 Reservoir in People Living with HIV.Viruses · 2026Review
- Dynamics of HIV reservoirs following repeated anti-SARS-CoV-2 vaccination.Frontiers in immunology · 2026Review
- Effects of inactivated COVID-19 vaccination on HIV viremia and reservoir size: a longitudinal cohort study.BMC infectious diseases · 2025Observational
- Within-Subtype HIV-1 Polymorphisms and Their Impacts on Intact Proviral DNA Assay (IPDA) for Viral Reservoir Quantification.Viruses · 2025Article
- Safety of Bacillus Calmette-Guérin Vaccination and Impact on HIV-1 Latent Reservoir Size in People With Treated HIV-1 Infection.Open forum infectious diseases · 2025Article
- Autologous HIV-specific T cell therapy targeting conserved epitopes is well-tolerated in six adults with HIV: an open-label, single-arm phase 1 study.Nature communications · 2025Article
- Safety Profile of COVID-19 Vaccines in HIV Patients Undergoing ART and Their Impact on Immune Recovery and HIV Reservoirs.Infectious diseases & immunity · 2024Article
- SARS-CoV-2 Modulation of HIV Latency Reversal in a Myeloid Cell Line: Direct and Bystander Effects.Viruses · 2024Article
- Increase in HIV reservoir and T cell immune response after CoronaVac vaccination in people living with HIV.Heliyon · 2024Article
- SARS-CoV-2 mRNA Vaccines Induce Greater Complement Activation and Decreased Viremia and Nef Antibodies in Men With HIV-1.The Journal of infectious diseases · 2024Article
- People Living With HIV Have More Intact HIV DNA in Circulating CD4+ T Cells if They Have History of Pulmonary Tuberculosis.Pathogens & immunity · 2024Article
- T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19.Science translational medicine · 2023Article
- Review
- Understanding nucleic acid sensing and its therapeutic applications.Experimental & molecular medicine · 2023Review
- Immunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older people with HIV.iScience · 2023Article
- Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir size.medRxiv : the preprint server for health sciences · 2023Article
- Prevention, treatment and cure of HIV infection.Nature reviews. Microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 6 institutions in 2 countries.
Eva M Stevenson *Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Sandra Terry *Department of Medicine, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0003-2620-5306
Dennis Copertino *Department of Medicine, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0002-3217-4713
Louise LeyreDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA.
Ali DaneshDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA.
Jared WeilerDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA.
Adam R WardDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0002-7038-5597
Pragya KhadkaDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA.
Evan McNeilDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA.
Kevin BernardDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA.
Itzayana G MillerDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA.
Grant B EllsworthDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA.
Carrie D JohnstonDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA.
Eli J FinkelszteinDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA.
Paul ZumboApplied Bioinformatics Core, Weill Cornell Medical College, New York, NY, USA.
Doron BetelDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0002-8006-7752
Friederike DündarApplied Bioinformatics Core, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0002-2301-112X
Maggie C DuncanFaculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
Hope R LapointeBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.ORCID 0000-0002-6847-9156
Sarah SpeckmaierBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Nadia Moran-GarciaBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Michelle Premazzi PapaDept of Microbiology Immunology and Tropical Medicine, The George Washington University, Washington, DC, USA.
Samuel NicholesDept of Microbiology Immunology and Tropical Medicine, The George Washington University, Washington, DC, USA.
Carissa J StoverDept of Microbiology Immunology and Tropical Medicine, The George Washington University, Washington, DC, USA.ORCID 0000-0001-5577-9910
Rebecca M LynchDept of Microbiology Immunology and Tropical Medicine, The George Washington University, Washington, DC, USA.ORCID 0000-0002-7188-8073
Marina CaskeyLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID 0000-0003-1727-8693
Christian GaeblerLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID 0000-0001-7295-8128
Tae-Wook ChunLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID, NIH, Bethesda, MD, USA.
Alberto BosqueDept of Microbiology Immunology and Tropical Medicine, The George Washington University, Washington, DC, USA.
Timothy J WilkinDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA.
Guinevere Q LeeDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0002-9412-886X
Zabrina L BrummeFaculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.ORCID 0000-0002-8157-1037
R Brad JonesDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA. rbjones@med.cornell.edu.ORCID 0000-0003-4470-1231
Cornell University · USGeorge Washington University · USAIDS Vancouver · CARockefeller University · USSimon Fraser University · CANational Institute of Allergy and Infectious Diseases · US
Funding
Disparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2MWeill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials UnitUM1AI069419 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI ROY M. GULICK · 2012 to 2026
$44.6MDeveloping, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6MREACH: Research Enterprise to Advance a Cure for HIVUM1AI164565 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Marina Caskey, R. Brad Jones · 2021 to 2026
$32.9MRole of Viral Reservoirs in the Pathogenesis of HIV DiseaseZIAAI000851 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CHUN, TAE-WOOK · 2009 to 2025
$29.3MBELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral EradicationUM1AI126617 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JONES, R. BRAD, NIXON, DOUGLAS F · 2016 to 2020
$28.1MMechanisms of CTL Resistance in HIV ReservoirsR01AI170245 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JONES, R. BRAD · 2022 to 2025
$3.0MCharacterization of Non-subtype B HIV-1 Reservoirs and its Association with Longitudinal Clinical OutcomesR01AI162221 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI LEE, GUINEVERE · 2021 to 2025
$2.1MCTL-Mediated Elimination of Replication Competent vs. Defective HIV Proviruses from Natural Latent Reservoirs: Roles of Antigen Specificity and Functional CharacteristicsR01AI131798 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JONES, R. BRAD · 2017 to 2021
$2.1MInsights into the dynamics of clonal expansion of genome-intact proviruses by examining longitudinal evolution of HIV proviral DNA compositionsR21AI150398 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI LEE, GUINEVERE · 2020 to 2021
$466kNCATS NIH HHS UL1 TR001866NCATS NIH HHS UL1 TR002384NIAID NIH HHS R01 AI131798NIAID NIH HHS R01 AI162221NIAID NIH HHS R01 AI170245NIAID NIH HHS R21 AI150398NIAID NIH HHS UM1 AI069419NIAID NIH HHS UM1 AI126617NIAID NIH HHS UM1 AI164565
Abstract
Efforts to cure HIV have focused on reactivating latent proviruses to enable elimination by CD8
Indexed as
CD8-Positive T-LymphocytesCOVID-19COVID-19 VaccinesHIV-1HIV InfectionsBNT162 VaccineCD4-Positive T-LymphocytesGranzymesHumansmRNA Vaccinesnef Gene Products, Human Immunodeficiency VirusRNA, MessengerSARS-CoV-2VaccinationVaccines, SyntheticVirus LatencyBNT162 VaccineCOVID-19 VaccinesGranzymesmRNA Vaccinesnef Gene Products, Human Immunodeficiency Virusnef protein, Human immunodeficiency virus 1nef protein, Human immunodeficiency virus 2RNA, MessengerVaccines, Synthetic
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.